This is an article is part II of the cancer series shared from Dr. Tsu-Tsair Chi of Chi’s Enterprise. This is the invaluable information for you to understand that everybody is looking for.

If you missed part I or would like to review this prior to reading part II, visit this link here.

Enjoy!

Glen Depke, Traditional Naturopath

Angiostop Inhibits Multiple Cancer Targets

By Dr. Tsu-Tsair Chi

What you should know…
  • Angiostop inhibits 5 growth factor receptors that are overexpressed in cancer: VEGFR, EGFR, FGFR, PDGFR, IGFR
    • VEGFR is a vital cancer target: it is expressed in ALL types of cancer
    • Angiostop inhibits IGFR. Currently there is no IGFR inhibitor in the market
  • Cancer patients often develop cancer drug resistance within a few months. Adding Angiostop provides better results and increases survival rate
  • At the first suspicion or diagnosis of cancer, take Angiostop immediately
  • Make sure to take Angiostop before and after cancer surgery or any type of invasive procedure to reduce the risk of recurrence and spread

Read on to learn more about Angiostop…

Attack Cancer through Multiple Pathways with One Supplement

When dealing with cancer, you have to remember two important things: cancer cells multiple rapidly and exponentially and they have multiple ways of growing. So you must start cancer therapy as soon as possible and you have to attack it from different angles. In the last newsletter, we started discussing Angiostop, a sea cucumber extract, which blocks angiogenesis and multiple receptor tyrosine kinases (RTKs) which drive cancer growth.

Angiostop is recommended immediately after cancer diagnosis or even if you already suspect cancer. If you are on conventional cancer therapy like chemotherapy or targeted drugs (RTK inhibitors), you still need Angiostop. Why? Because many of these conventional cancer therapies have limitations that Angiostop is able to address such as drug resistance, side effects, limited cancer targets and more. Here we will discuss these limitations and how Angiostop can fill in the gaps that these conventional treatments are not able to provide.
First, we reiterate that among more than 50 RTKs, Angiostop inhibits 5 of the most important ones associated with cancer:
VEGFR – Vascular Endothelial Growth Factor Receptor
EGFR – Epidermal Growth Factor Receptor
PDGFR – Platelet-Derived Growth Factor Receptor
FGFR – Fibroblast Growth Factor Receptor
IGFR – Insulin-like Growth Factor Receptor

When dealing with cancer, you have to remember two important things: cancer cells multiple rapidly and exponentially and they have multiple ways of growing. So you must start cancer therapy as soon as possible and you have to attack it from different angles. In the last newsletter, we started discussing Angiostop, a sea cucumber extract, which blocks angiogenesis and multiple receptor tyrosine kinases (RTKs) which drive cancer growth.

Angiostop is recommended immediately after cancer diagnosis or even if you already suspect cancer. If you are on conventional cancer therapy like chemotherapy or targeted drugs (RTK inhibitors), you still need Angiostop. Why? Because many of these conventional cancer therapies have limitations that Angiostop is able to address such as drug resistance, side effects, limited cancer targets and more. Here we will discuss these limitations and how Angiostop can fill in the gaps that these conventional treatments are not able to provide.
First, we reiterate that among more than 50 RTKs, Angiostop inhibits 5 of the most important ones associated with cancer:
VEGFR – Vascular Endothelial Growth Factor Receptor
EGFR – Epidermal Growth Factor Receptor
PDGFR – Platelet-Derived Growth Factor Receptor
FGFR – Fibroblast Growth Factor Receptor
IGFR – Insulin-like Growth Factor Receptor

Inhibit Several Growth Factors at the Same Time

Multiple RTK targets also mean multiple applications in various types of cancer. Different cancer types overexpress different RTKs (Table 2). One of the limitations of conventional cancer therapies, even targeted drugs, is that they target only a limited number of RTKs. As mentioned, VEGFR is a common target of many of these drugs. We see in Table 2 that again VEGFR is expressed in 100% of the cancer types so inhibiting it is essential. But you also need to simultaneously inhibit all of the other RTKs in order to maximize the results.

 CASE REPORTS: Multiple Cancer Targets Mean Better Results and Better Survival

For instance, let us look at this breast cancer case.

F. Akbarpour, MD from CA, has an 81 y/o/f patient with breast cancer. She had a mastectomy but the cancer recurred as angiosarcoma in the breast. She was given Sutent (25 mg/day) with no apparent effect. The dose was doubled but still there were no results. Then Dr. Akbarpour reduced the Sutent dose and added Angiostop. After about 4 months, the angiosarcoma cleared.

Sutent is a targeted drug that inhibits VEGFR and PDGFR but it does not inhibit EGFR, FGFR and IGFR. This explains why Sutent had limited effect even after doubling the dose. It was only after adding Angiostop that the desired results were achieved.

Another example is lung cancer. In the case below, the patient took Tarceva, an EGFR inhibitor drug and the best targeted drug for lung cancer, along with Angiostop, Myomin and other cancer supplements, Revivin, Asparagus Extract and Reishi Spore Extract. Lung cancer is also related to high estrogen so in the following case, Myomin was also recommended.

Antoine E., a 60 y/o/m from FL, was diagnosed primary pulmonary adenocarcinoma in his lung in 2010 at age 53. Surgery removed the mass. However, within two years, the cancer recurred and spread from his left lung to his right lung and chest cavity. The large mass in his chest cavity was increasing at a rapid rate. At that time, it had grown to the size of a grapefruit and considered inoperable Stage 4 adenocarcinoma. He was given 3 to 6 months to live. He underwent chemotherapy. In April 2012, he added taking Angiostop, Revivin, Reishi Spore Extract, Asparagus Extract, Myomin and OxyPower. He also took Tarceva. In December 2013, his PET scan revealed no tumor. He continues to take the supplements and Tarceva is determined to be cancer free. In his words, his oncologist told him, “I am their only patient on Tarceva living that long.”Tarceva is only good for 9 months when patients acquire drug resistance.

Referring again to Table 2 above, lung cancer expresses VEGFR, EGFR, PDGFR, FGFR and IGFR. Tarceva only inhibits EGFR, so it is not enough really to address all the aspects of lung cancer. Antoine’s results are favorable because he is also taking Angiostop which inhibits all these RTKs.

Furthermore, studies indicate that if EGFR mutates, then RTK inhibitors like Tarceva can only increase survival by 10 months. In fact, as mentioned, resistance to Tarceva develops after 9 months (Source: Chinese World Journal Daily News. Nov 9, 2010: F2).

Case Report: Angiostop Helps Manage CEA in Lung/Colon Cancer and Increase Survival

In another case, a 64 y/o/m patient who was a smoker found blood in the stool in June 2011. He had no insurance at that time so he started taking Myomin, Angiostop and Revivin. The following year, at age 65, he finally got insurance. He was diagnosed with lung cancer and had subsequent lung surgery. The surgeon was amazed it did not metastasize. In March 2013, he was diagnosed with colon cancer and two sections of his colon were removed. He never underwent any chemotherapy or radiation. In Nov 2014, his CEA rose to 9.3 so his oncologist added Tarceva in Dec 2014. All this time he has been taking Angiostop (6-9 capsules) and Myomin (4-6 capsules) and his cancer marker, CEA, has been controlled. In May 2016, CEA went up to 9.7 so he increased his Angiostop dose (5 BID). His CEA dropped to 7.3 two months later (Table 3).

We see that in this case Angiostop and Myomin have been able to manage this patient’s lung and colon cancer. We see his progress through his CEA, which is the main cancer marker used to monitor lung and colon cancer. To reiterate, lung cancer expresses 5 RTKs. Colon cancer expresses 4 RTKs, VEGFR, EGFR, FGFR and IGFR. This patient’s favorable results are due to Angiostop inhibiting all 5 RTKs in both lung and colon cancer. Usually the chemotherapy drugs, 5-FU or Xeloda, are recommended for colon cancer. But these drugs work differently in that they kill both cancer and normal cells. Or the targeted drug Avastin, a VEGFR inhibitor, is also recommended for colon cancer. In this case, adding Tarceva has helped but only for a limited period of time. Remember, Tarceva only inhibits EGFR and is only good for about 9 months. Indeed in this case, his CEA rose up to 9.5 again about a year after adding Tarceva. This means that it has likely lost its efficacy. Increasing the dose of Angiostop after that helped reduce his CEA again.

Angiostop Shown to Inhibit IGFR, FGFR, VEGFR in Colon Cancer Research Genetic Cancer Centre Test (RGCC)

In an RGCC Genetic test, Angiostop was shown to inhibit IGFR by 19%, FGFR by 24% and VEGFR by 26% in colon cancer (Figure 1). Any cancer patient doing the cancer genetic testing should know that any drug or supplement tested and shown to immediately reduce RTKs by more than 10% is considered an excellent anti-cancer agent. What makes these results even more impressive is that no IGFR inhibitor drug has yet been approved. The fact that Angiostop inhibited IGFR in an actual cancer patient is of great significance.

Angiostop Activates Caspases to Induce Cancer Apoptosis

The RGCC Genetic Test also showed that Angiostop increases Caspase 3 and Cytochrome C activity.

Caspases, in particular, are the primary regulators of cancer apoptosis or cell death. Many cancer cells are able to avoid cell death and proliferate because of either a lack of caspases or because of reduced caspase function. Angiostop is able to activate not only Caspase 3, as seen in the RGCC test, but four caspases (Caspase 3, 7, 8, 9), enabling it to more effectively induce apoptosis (Figure 2).

Figure 2 summarizes the multiple cancer targets that Angiostop addresses. In the tyrosine kinase pathway (blue rectangle in Figure 2), Angiostop blocks important RTKs (VEGFR, EGFR, FGFR, PDGFR, IGFR, Akt, ERK, FAK and Paxillin). Therefore, it can affect gene regulation and reduce cell proliferation, migration and angiogenesis. Furthermore, its activation of several caspases and other apoptosis factors like Cytochrome C, Bcl-2 and Bax, makes it effective in inducing cancer apoptosis.

Take Angiostop immediately after diagnosis or suspicion of cancer

Take Angiostop immediately after diagnosis or suspicion of cancer

As soon as you have any suspicion of a growth or immediately after cancer diagnosis, take Angiostop as quickly as you can. Or if you are lacking any moons on your nails and have teeth marks, or when you have other cancer physical signs (see Dr. Chi’s Fingernail and Tongue Analysis book), dense breasts or high PSA, you can start taking Angiostop for prevention.

Even if biopsy shows only a non-cancerous tumor, Angiostop is still highly recommended to ensure that it does not become cancerous. Take 3 capsules, 2 time daily for tumors or 3 capsules, 3 times daily for cancer and then consult a specialist.

If taking Angiostop 3 times a day, take each dose about 7 to 9 hours apart with some food. Cancer cells grow fast at nighttime. Normal cells typically double in number every 3 days but cancer cells double every 9 hours. Cortisol is typically down at night and immunity is low, allowing cells to multiply even faster at nighttime. So it is best to take one dose at night and first thing in the morning.
the blank white banner with two black arrows
Take Angiostop before cancer surgery or any type of invasive procedure
Angiostop is necessary if you are undergoing cancer surgery or any other type of invasive procedure. Studies show that the chance of the cancer recurring and spreading increases after surgery. In fact, one study shows that the risk of recurrence and metastasis is 50% within 2 years after breast, colon and lung cancer surgery, etc. Researchers recommend an angiogenesis inhibitor before and after surgery to minimize this recurrence (Source: International Journal of Surgery. 2005;3(3):179-87; Lancet. 2002).Keep in mind that cancer cells can grow exponentially and quickly triggered by angiogenic stimulators so you need to also quickly suppress angiogenesis. In any type of surgery or invasive procedure, the healing process triggers the release of angiogenic stimulators. If there are any cancer cells, then these factors can trigger growth.If undergoing cancer surgery, stop taking Angiostop a day before surgery and resume immediately after surgery as soon as you are able. Typically, 3 capsules, 2-3 times daily of Angiostop is recommended for 2 years after cancer surgery.Besides cancer surgery, Angiostop is also recommended before any invasive procedure like biopsy, lumpectomy, colonoscopy or endoscopy to avoid any unintentional spread in case there is cancer. Angiostop is recommended (2 capsules, 2-3 times daily) for at least a month before any of these procedures. If cancer is found after a biopsy, a high dose of Angiostop would still be recommended after the procedure. And in the meantime, your physician can order tests (e.g., to check your WBC, etc.) to determine which treatments will be suitable therapy for you. Whichever treatment is given, you still need to add Angiostop.

It is important to stress the need for angiogenesis inhibitors, or any treatment for that matter, before and after cancer surgery to prevent any unwanted effect, such as in these cases, even if surgeon says there are “clear margins.”

S.L. had an abnormal mammogram in 2009 at age 53. She then had a biopsy where they found ductal carcinoma in situ (0.03mm). She underwent a lumpectomy but did not do anything after that. Two years later, she found that her cancer has recurred and metastasized.

D. Zamikoff, DC from FL, has a 71 y/o/m patient who had surgery for renal cell carcinoma (no medication due to clear margins). In Jan 2015, the cancer spread to his lungs (3 nodules found).

N. T., 60 y/o/f from CA, had radiation for a thyroid tumor in 2010 but her cancer markers were always high. Even if cancer markers are elevated and the cancer is undetectable, like in this case, then you should still take Angiostop. So this patient took Angiostop, Myomin, Vein Lite, OxyPower. After 3 months, her CEA and CA 19-9 levels reduced to normal level and she had better energy.

Angiostop can be taken by itself or with conventional cancer therapy
Some cancer drugs, even targeted drugs (RTK inhibitors), must be used in conjunction with chemo, radiation or other targeted therapies in order to suppress cancer from different angles. Angiostop, by itself, already has targets cancer through multiple pathways, such as inhibiting angiogenesis or proliferation or inducing apoptosis.If you are on cancer drugs, surgery or radiation, you can still take Angiostop. In fact, there is a synergistic effect of combining Angiostop with these therapies. Furthermore, adding Angiostop will help address the limitations that conventional cancer therapies have, such as side effects or drug resistance. Angiostop is a well-tolerated supplement with minimal side effects. Patients can also take it long term and still get results unlike many cancer drugs. Patients can develop drug resistance quickly and only prolong survival for a short period of time. For instance, Tarceva is only good for 9 to 10 months. After that, it loses its effect. Nexavar, a multiple RTK inhibitor for kidney, liver and thyroid cancer, increases survival by only 3 months.
SUMMARY
Every day, there are approximately 1,600 cancer deaths in the United States. Overall, one out of three deaths is caused by cancer. But cancer doesn’t have to be a death sentence. If we detect it early enough then there are natural solutions that will help us achieve better outcomes and survival rates. Taking Angiostop immediately after cancer diagnosis or once cancer is suspected can make a huge difference.Multiple Pathways
Angiostop targets cancer through multiple pathways: it inhibits angiogenesis by blocking several RTKs (VEGFR, EGFR, PDGFR, FGFR, IGFR) and it also induces apoptosis by activating several caspases. You have to address the many factors that are fueling cancer growth in order to fully suppress it. For cancers that express IGFR, or for those that are estrogen-related, you need to add Myomin.Take immediately after cancer suspicion or diagnosis
So for any type of cancer, take Angiostop immediately once the tumor or cancer is discovered. It is important to control the growth as soon as possible. Then consult a specialist.Take before and after cancer surgery or procedure
If you have to undergo surgery or any type of invasive procedure (biopsy, lumpectomy, colonoscopy, endoscopy, etc.), take Angiostop at least a month before the procedure. This will help reduce the risk of recurrence or spread. You can stop taking Angiostop a day before the surgery and resume taking it immediately after the procedure or as soon as you are able.

Overcome drug resistance that many cancer drugs have by adding Angiostop
If you are on conventional cancer treatment, you can still take Angiostop with it. Adding Angiostop will actually help address the limitations that many cancer treatments have like drug resistance, side effects, or limited targets.

Essentially, Angiostop inhibits pathways that allow cancer cells to proliferate and tumors to grow and, at the same time, it promotes pathways that allow cancer cells to die.

the blank white banner with two black arrows
A special thank you to Dr. Chi for allowing us to share this inspiring information!

If you have any comments or questions regarding this article please post this on our Facebook page or on our Twitter page for us to address personally.

Apply for Your Opportunity to “Feel Young Again” With Depke Wellness

“The products on this page have not been reviewed by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.”